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Encapsulation of more than one active pharmaceutical ingredient into nanocarriers such as 
liposomes is an attractive approach to achieve a synergic drug effect and less complicated dosing 
schedules in multi-drug treatment regimes. Liposomal drug delivery in acne treatment may 
improve drug efficiency by targeted delivery to pilosebaceous units, reduce adverse effects and 
improve patient compliance. We therefore aimed to co-encapsulate benzoyl peroxide (BPO) and 
chloramphenicol (CAM) into liposomes using the novel liposome processing method – dual 
asymmetric centrifugation (DAC). Liposomes were formed from soybean lecithin, propylene 
glycol and distilled water (2:1:2 w/v/v ratio), forming a viscous liposome dispersion. Liposomes 
containing both drugs (BPO-CAM-Lip), single-drug (BPO-Lip and CAM-Lip), and empty 
liposomes were prepared. Drug entrapment of BPO and CAM was determined by a newly 
developed HPLC method for simultaneous detection and quantification of both drugs. 
Encapsulation of around 50% for BPO and 60% for CAM respectively was obtained in both single-
drug encapsulated formulations (BPO-Lip and CAM-Lip) and co-encapsulated formulations (BPO-
CAM-Lip). Liposome sizes were comparable for all liposome formulations, ranging from 130 to 
150 nm mean diameter, with a polydispersity index < 0.2 for all formulations. CAM exhibited a 
sustained release from all liposomal formulations, whereas BPO appeared retained within the 
liposomes. BPO retention could be attributed to its poor solubility. However, HaCaT cell toxicity 
was found dependent on BPO released from the liposomes. In the higher concentration range (4% 
v/v), liposomal formulations were less cytotoxic than the corresponding drug solutions used as 
reference. We have demonstrated that DAC is a fast, easy, suitable method for encapsulation of 
more than one drug within the same liposomes.  
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1.  Introduction 
Acne vulgaris (or simply acne), is a chronical inflammatory skin disease, affecting approximately 
90% of the global population during adolescence. However, the skin condition might also continue 
into adulthood, having a severe impact on self-esteem and general quality of life (Williams et al., 
2012). Current guidelines for management of acne recommend combination therapy with topical 
retinoid and benzoyl peroxide (BPO) as first-line treatment in mild to moderate acne (Walsh et al., 
2016; Zaenglein et al., 2016).  
The use of multiple drugs in combination to achieve a synergistic effect in treatment of diseases is 
a well-known strategy for improved therapeutic outcome, and has been adapted as standard first-
line treatment in several diseases (Durante-Mangoni et al., 2014; Fischbach, 2011; Landewé et al., 
2002). The use of combination therapy is also likely to increase in the future as the emergence of 
antibiotic resistant pathogens is associated with therapeutic failure, forcing us to develop new drugs 
and treatment strategies in order to assure future availability of treatment for these pathogens 
(Durante-Mangoni et al., 2014; Walsh et al., 2016). The drawback of conventional combination 
therapy is that it is more complex compared to monotherapy and often involves the use of several 
dosage forms that increase the possibility of patient non-adherence during the treatment. Co-
encapsulation and co-delivery of drugs using nanocarriers such as liposomes has the potential to 
simplify the therapy, since drugs incorporated into the same carrier will be delivered to the target 
simultaneously.  
Today, chloramphenicol (CAM) is mainly used for treatment of eye and ear infections, as its oral 
and intravenous use are limited by its bone marrow toxicity. However, topical administration of 
CAM for treatment of local invasive skin infections offers rapid delivery, and since nanocarriers 
might circumvent the limitations of the drug associated with systemic toxicity, CAM is already 
recognized as a good candidate for encapsulation into nanocarriers for topical treatment of skin 
infections (Ingebrigtsen et al., 2016; Kalita et al., 2015). Moreover, it has been demonstrated that 
old antibiotics such as CAM remain active against prevalent resistant bacterial isolates owing to 
their rather low-level use in the past (Fayyaz et al., 2013). 
Although BPO is preferred first-line therapy for the treatment of mild to moderate acne, it is known 
that BPO might cause local adverse reactions such as cutaneous irritation or dryness, erythema and 
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scaling (Foti et al., 2015). In addition, BPO is also prone to degradation and is unstable in solution 
(Chellquist and Gorman, 1992).  
Liposomes were first suggested as a topical drug delivery system by Mezei and Gulasekharam 
already in 1980  (Mezei and Gulasekharam, 1980), and have been studied quite intensively as skin 
nanocarriers since then; however co-encapsulation of multiple drugs into liposomes is a relatively 
new approach. Recently, several studies have investigated the potential of this approach, and 
reported liposomal encapsulation of drug combinations such as topotecan/vincristine (Zucker et 
al., 2012), irinotecan/doxorubicin for anticancer therapy (Shaikh et al., 2013), and  BPO/tretionin 
combination for the treatment of acne (Gupta et al., 2010). 
Dual asymmetric centrifugation (DAC), is a laboratory mixing system, which differs from 
conventional centrifugation by adding a secondary rotation around its own axis (Massing et al., 
2008). The suitability and versatility of this new technique for liposome production has already 
been demonstrated in a number of studies (Adrian et al., 2011; Ingebrigtsen et al., 2016; Massing 
et al., 2008; Meier et al., 2015; Parmentier et al., 2014; Tian et al., 2010). Liposomes can be 
produced in a gentle way, and aseptic manufacturing is facilitated, as the sample holder is a closed 
container (Hirsch et al., 2009). Since the technique provides a closed system and eliminates the 
need of organic solvents, it has several advantages compared to other available production methods 
(Massing et al., 2008; Wagner and Vorauer-Uhl, 2011). Concentrated vesicular phospholipid gels 
(VPGs) are formed as an intermediate product in this process, making it especially suitable for 
obtaining high liposome content in secondary vehicles such as creams, lotions or hydrogels 
(Ingebrigtsen et al., 2016).  
In this study, we aimed to investigate the suitability of DAC for the production of co-encapsulated 
BPO and CAM in liposomes. In addition, a new HPLC method for simultaneous detection of BPO 
and CAM was developed to facilitate fast and easy drug quantification during characterization of 
the investigated formulations. The system’s toxicity was compared to single-drug liposomes and 






Acetone, acetonitrile CHROMASOLV®, 99.8% anhydrous acetic acid, ammonium molybdate, 
Luperox® A75FP (75% benzoyl peroxide; remainder water), chloramphenicol, chloroform, 
Dulbecco's Modified Eagle's Medium with 1% L-glutamine, ethanol 96%, Fiske-Subbarow reducer 
agent, isopropanol, monobasic potassium phosphate, RPMI-1640 medium, sodium chloride and 
Triton X-100 were purchased from Sigma-Aldrich Chemie (Steinheim, Germany). Disodium 
hydrogen phosphate dihydrate, and 30% water-free hydrogen peroxide were purchased from Merck 
(Darmstadt, Germany). Concentrated sulfuric was the product of May and Baker LTD (Dagenham, 
England). Propylene glycol was purchased from NMD – Norwegian Medical Depot (Oslo, 
Norway). Lipoid S 100 (soybean lecithin, > 94% phosphatidylcholine) was a kindly provided gift 
from Lipoid GmbH (Ludwigshafen, Germany). 
 
3. Methods 
3.1. Liposome preparation  
Liposomes were made by dissolving 200 mg Lipoid S 100 (PC) in 10 ml of acetone:chloroform 
(1:2 v/v) together with 3 mg BPO (equal to 4 mg Luperox® A75FP)  and/or 20 mg of CAM.  
For all formulations, the organic solvents were removed at room temperature under a stream of 
nitrogen using the setup described elsewhere (Ingebrigtsen et al., 2016). The lipid film was 
hydrated with 100 µl propylene glycol (PG) and 200 µl distilled water. Finally, glass beads (Ø = 2 
mm) equal to 50% (w/w) of the total sample weight were added before storage overnight at 4 °C.  
Liposome size was reduced by DAC using a Speedmixer (DAC 150.1 FVZ-K Speedmixer, 
Synergy Devices Ltd., High Wycombe, UK). All samples were processed for 40 minutes at 
maximum speed, corresponding to 3500 rpm. The VPGs were diluted with distilled water to 




3.2. Liposome characterization 
3.2.1. Entrapment efficiency 
Free unentrapped BPO crystals were separated from entrapped liposomal BPO by filtration through 
a 0.22 µm filter (Acrodisk, Pall Corporation, New York, USA). Total amount of BPO in the filtrate 
and in the original sample was quantified by HPLC analysis. Drug entrapment of BPO was 
calculated as described in Equation 1. 
Equation 1:   
Amount of BPO filtrate
Amount of BPO original sample 
× 100 =  Entrapment efficiency (%) 
The entrapment of CAM was determined after separation of unentrapped CAM from the 
formulations by dialysis. Liposomal samples were dialyzed against distilled water using a cellulose 
membrane with a Mw cut-off of 12–14000 Da (Medicell International Ltd., London, UK). After 4 
hours dialysis, CAM concentration was quantified by HPLC. Drug entrapment efficiency of CAM 
was calculated using Equation 2. 
Equation 2: 
Amount of CAM dialyzed sample
Amount of CAM original sample 
× 100 =  Entrapment efficiency (%) 
3.2.2. Size measurements 
Size measurements were performed on a Zetasizer Nano ZS (Malvern Instruments Ltd., Malvern, 
UK), using the following setting; sample temperature 25 °C, equilibration time 180 seconds, and 
number of runs was set to automatic. All liposome dispersions were diluted 1:100 with filtered 
distilled water prior to measurement. 
3.2.3. Zeta-potential measurements 
The zeta-potential of our liposome dispersions was also determined using the Zetasizer Nano ZS 
(Malvern Instruments Ltd., Malvern, UK), with the same equilibration time and measurement 
temperature as for the size measurements (3.2.2). All measurements were performed in triplicate, 
using the automatic setting for drive voltage and number of runs per measurement. Liposome 
samples were diluted 1:10 with filtered distilled water prior to measurement. 
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3.2.4. In vitro drug release 
Franz diffusion cells (PermeGear, Bethlehem, USA) with a surface area of 0.64 cm2 and receptor 
volume of 5.0 ml were used for the drug release studies. The cells were mounted in a stirrer (V6A-
02, PermeGear, Bethlehem, USA) and connected to a heating circulator (F12-ED, Julabo 
Laboratechnik, Seelback, Germany). All experiments were performed in triplicates at 25 °C using 
a cellophane membrane (Max Bringmann KG, Wendelstein, Germany). Phosphate buffered saline 
(PBS) (2.98 g/l disodium hydrogen phosphate dihydrate, 0.19 g/l monobasic potassium phosphate, 
and 8 g/l sodium chloride) with pH 7.4 was the chosen acceptor phase for these experiments. Free 
drug was removed from the liposome dispersion (as described in section 3.2.1) prior to testing. The 
sample volume (both liposome formulations and the control drug solution) in the donor 
compartment was 300 µl. Samples of 500 µl were collected from the acceptor chamber every hour 
for 8 hours. All samples were subsequently analyzed by HPLC. After each sampling, the acceptor 
cells were refilled with 500 µl fresh acceptor phase. To avoid evaporation during the experiments, 
a triple layer of parafilm was used to cover both the donor compartment and the sampling port to 
the acceptor chamber. 
3.3. HPLC analysis 
A HPLC method was developed to facilitate simultaneous detection and analysis of BPO and 
CAM. The instrumentation used comprised a Waters e2795 Separations Module, a Symmetry C18 
column guard and a XSELECT CSH C18 (2.5 mm; 3.0 75 mm) column XP connected to a Waters 
2489 UV/Visible detector (Waters, Dublin, Ireland). Detection wavelength was set to λ = 278 nm. 
Analyses were run using a flow rate of 0.6 ml/min and gradient flow conditions (Figure 1) at 25 
°C, with an injection volume of 20 µl, run time of 10 minutes and a delay of 2 minutes between 
each injection. 
For the in vitro drug release studies (section 3.2.4), the analyses were performed in dual wavelength 
mode, with detection at both 238 nm and 278 nm. Since BPO has a higher absorbance at 238 nm, 
this wavelength allowed a lower BPO concentration to be quantified. 
3.4. Quantification of lipids 
The amount of lipids in the liposome formulations were quantified by a phosphorus assay (Bartlett, 
1959) with modifications previously described by our group (Ingebrigtsen et al., 2016). In short, 
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liposomes (50 µl) were diluted up to a total volume of 10 ml with distilled water. After dilution, 1 
ml of each sample was mixed with 0.5 ml 10 N sulfuric acid and heated at 155 °C for 3 hours. Two 
drops of 30% water-free hydrogen peroxide were then added, before the samples were heated again 
at 155 °C for an additional 1.5 hour. After heating, samples were mixed with 4.6 ml 0.22% 
ammonium molybdate solution and 0.2 ml Fiske-Subbarow reducer agent before additional 7 
minutes heating at 100 °C. Samples were finally analyzed calorimetrically at λ = 830 nm using a 
SpectraMax 190 Microplate Reader (Molecular Devices, California, USA). 
3.5. Cell viability assay 
Cell viability was tested according to a modified method originally described by Mosmann 
(Mosmann, 1983). HaCaT cells were seeded on 96-well plates with a density of 2 × 105 cells/ml. 
Cells were cultured overnight in a humidified atmosphere of 5% CO2 at 37 °C. Liposomal samples 
were applied in the assay after removal of unentrapped drug (as described in section 3.2.1). The 
investigated formulations, both liposome dispersions and ethanol drug solutions, were added after 
dilution in growth medium resulting in final sample concentrations between 0.1 and 4.0 % (v/v), 
corresponding to between 5 to 200 µg/ml CAM and 0.75-30 µg/ml BPO. After the treatment, cells 
were incubated for 4 hours before the MTT solution was added (5 mg/ml in PBS). After two 
additional hours of incubation, the crystallized formazan was dissolved in acidified isopropanol 
(0.04 N). The absorbance of the reduced MTT (formazan) was determined at λ = 590 nm on a 
SpectraMax 190 Microplate Reader (Molecular Devices, California, USA).  
Cell survival/viability was determined relative to the positive and negative controls; 2% (v/v) triton 
solution and growth medium, respectively.  
3.6. Statistical analysis 
All statistical analyses were performed using SigmaPlot for Windows version 13 (Systat Software, 
Erkrath, Germany) and a confidence interval of 95%. 
 
4. Results and discussion 
Liposomes have already been proposed as a carrier to improve the effect and reduce adverse effects 
of different drugs used in the topical treatment of acne (Castro and Ferreira, 2008; Vyas et al., 
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2014), such as clindamycin (Škalko et al., 1992), retinoid derivative tretinoin (Patel et al., 2000), 
adapalene (Kumar and Banga, 2016) and BPO (Patel et al., 2001). Liposomes are regarded to be 
biocompatible carriers that have the ability to accommodate both hydrophilic and lipophilic 
compounds while also protecting the compounds from the external environment. Co-encapsulation 
of BPO and CAM into liposomal nanocarriers might therefore provide therapeutic advantages, such 
as controlled release, improved drug penetration, and improved efficiency through increased 
stability in the carrier (Vanić, 2015).   
To the best of our knowledge, no studies have so far investigated the potential of using DAC as a 
processing method for the entrapment of more than one drug into the same liposomes. If proven 
feasible, this will make DAC an even more versatile manufacturing method for liposomes. The 
possibility of performing both the size reduction of liposomes, and mixing them into a final vehicle 
(such as liniments, hydrogels or creams) in high concentrations using only one machine, makes 
this method especially relevant for topical skin formulation intended for treatment of damaged or 
diseased skin. Moreover, the method offers a potential to perform the whole manufacturing process 
in aseptic conditions. 
However, the production of liposomes containing more than one drug represents not only a 
processing challenge, but also an analytical one. Thus, we first had to develop a HPLC method for 
simultaneous quantification of CAM and BPO, needed in further characterization and evaluation 
of the prepared liposomal formulations. 
 4.1. Simultaneous detection of BPO and CAM 
HPLC methods for determination and quantification of CAM (Boer and Pijnenburg, 1983; Burke 
et al., 1980; Ingebrigtsen et al., 2016; Sample et al., 1979) and BPO (Burton et al., 1979; Saiz et 
al., 2001) as a single drug have already been described in the literature. However, no reports on co-
determination were available and we aimed to develop a time-efficient HPLC method capable of 
simultaneous detection of the two drugs. 
The established in-house HPLC method for determination and quantification of CAM 
(Ingebrigtsen et al., 2016) was the starting point for the development of this novel HPLC method. 
First change made was regarding the mobile phase, where the organic solvent was changed from 
methanol to acetonitrile, as BPO has poor stability in methanol and decomposes readily even at 25 
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°C (Hongo et al., 2006). Next, the mobile phase composition and flow rate were adjusted, until 
BPO and CAM were adequately separated and proper retention times were obtained. The isocratic 
elution with 55% (v/v) acetonitrile and 45% (v/v) 0.1% acetic acid in MilliQ-water, was changed 
to a gradient elution, increasing the acetonitrile content linearly over 1 min to reach 95% (v/v) after 
4 minutes run time (Figure 1). This, together with an increase in a flow rate from 0.4 to 0.6 ml/min 
allowed us to elute and detect both CAM and BPO with retention times of 1.5 and 6.8 minutes, 
respectively (Figure 2). As the optimal absorption wavelength for BPO and CAM is λ = 238 nm 
and λ = 278 nm, respectively, these wavelengths were initially chosen for our dual wavelength UV-
detector. However, since both drugs gave sufficient absorption using single wavelength mode at λ 
= 278 nm, with drug concentrations ranging from 2.5 to 80.0 µg/ml, single wavelength mode was 
applied for most analyses. In the given concentration range of the drugs, the calibration curves had 
r2-value of 0.9998 for CAM and 0.9999 for BPO, respectively. Limit of detection and limit of 
quantification for CAM were determined to be 0.6 and 1.9 µg/ml, and 0.2 µg/ml and 0.7 µg/ml for 
BPO, respectively. This HPLC method thus satisfied our analytical requirements for further 
characterization of liposomal drug formulations and a suitable run time of 10 minutes was applied 
in the method. 
 






Figure 2: Representative HPLC chromatogram indicating simultaneous detection of both CAM 
(A, RT = 1.5 min) and BPO (B, RT = 6.8 min) at a concentration of 2.5 µg/ml, detected at 278 
nm. 
 
4.2. Liposome characteristics 
Co-encapsulation of two or more active ingredients into the same liposomal bilayer may change 
the characteristics of the liposomes in different ways, depending on the lipophilicity, size and 
charge/polarity of the drugs entrapped/incorporated. If the two drugs interact with each other, the 
release profile of the individual drug from the liposome carrier might change, ultimately 
influencing the biological effects of the drug. We therefore aimed to compare single-drug 
liposomes with the dual-drug containing liposomes. The DAC method has already been proven to 
circumvent some limitation of conventional liposome preparation methods, enabling processing of 
concentrated liposome dispersions with defined size distribution, high drug encapsulation ratios 
and a low polydispersity index (PI) (Ingebrigtsen et al., 2016; Massing et al., 2008). For 
optimization of the different formulations, we therefore aimed to make as few changes as possible 
to the already established DAC liposome processing method (Ingebrigtsen et al., 2016).  
4.2.1. Drug entrapment and size distribution 
As seen in Table 1, only minor and insignificant differences in the size and size distribution were 
observed between empty, single- and dual-drug containing liposomes made by DAC. Results 
indicated low PI (< 0.2), and the mean liposome size varied from 131.6 ± 9.1 nm (empty liposomes) 
to 146.2 ± 7.6 nm (BPO-lip), respectively. These results shows that the DAC method give 
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reproducible results regarding the mean size and size distribution, independently of which drug is 
loaded into the carrier, at least for these four formulations. It is also encouraging that the PI values 
obtained are so low. Our previous work (Ingebrigtsen et al., 2016), showed that CAM-containing 
liposomes (CAM-Lip) prepared with DAC, but without PG added, exhibited a PI of 0.13 ± 0.03. 
This also demonstrate the robustness and reproducibility of the DAC method. Both BPO and CAM 
had no impact on the liposome size in the concentrations applied. Moreover, no significant 
difference in ζ-potential was observed between the different formulations. Considering the 
entrapment efficiency, the entrapment of BPO and CAM in the combined liposomes (BPO-CAM-
Lip) proved to be very similar to the entrapment of the two drugs in respective single-drug 
liposomes (BPO-Lip and CAM-Lip), indicating that BPO and CAM are not affected by the 
presence of the other drug (Table 1). The observed lack of interaction between BPO and CAM 
might be explained by the higher lipophilicity of BPO (log Kow = 3.46) compared to CAM (log Kow 
= 1.14). The higher lipophilicity of BPO results in a stronger association with the lipid bilayer as 
compared to CAM; thus it can be postulated that BPO is accommodated within the lipid bilayers 
whereas CAM is mostly entrapped within the aqueous part of the vesicles.   
Interestingly, the entrapment efficiency for CAM in both the combination and single-drug 
formulation was higher than the entrapment value of 49.7 ± 2.8 % obtained in our previous study 
(Ingebrigtsen et al., 2016). This increase in drug entrapment might be explained by the increased 
centrifugation time from 2 minutes and 55 seconds to a total of 40 minutes, allowing for a more 
thorough mixing of PC and CAM. The improved entrapment values obtained with increased mixing 
time; drug:lipid ratios of 60.6 ± 3.3 and 60.7 ± 2.0 µg/mg, compares well with previously reported 
liposomal CAM-entrapment values reported with the proliposome method; drug:lipid ratio of 
62.7 ± 8.6 μg/mg (Pavelić et al., 1999). Compared to other preparation methods, the CAM-
encapsulation values obtained by DAC, however clearly exceeds the reported encapsulation values, 
i.e. CAM-encapsulation values of 32.5 ± 2.8 μg/mg was obtained for filter extruded liposomes 
(Engesland et al., 2015), although the authors prepared larger liposomes of around 670 nm in 
diameter. Also, previous studies in our group found that the encapsulation efficiency of 
approximately 30% (drug:lipid ratio = 31.12 ± 0.15 μg/mg) was achievable for CAM-liposomes 
prepared by probe sonication (Ingebrigtsen et al., 2016). Thus, the increased encapsulation 
achieved by DAC might be explained by the reduced water content in-between the liposome 
vesicles during processing and the high lipid content of VPGs. The limited availability of water to 
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solubilize in for CAM, forces a higher amount of drug to associate either with the lipid bilayers of 
the liposomes or the aqueous space within the liposomes. 
An entrapment efficiency of 48 ± 8.1% (BPO-CAM-Lip) to 51 ± 7.7% (BPO-Lip) was obtained 
for BPO, corresponding to a drug:lipid ratio of 7.2 to 7.7 µg/mg. This is comparable to the 
entrapment efficiency presented in percentage previously reported by Patel et al. (Patel et al., 2001), 
where six liposome formulations were made with different composition of the lipid bilayer, mixing 
PC and cholesterol in different molar ratios. However, since entrapment values were only given as 
percentage, the liposomes had different composition, and larger multilamellar vesicles were 
applied in this study, a direct comparison is not possible. The presence of cholesterol is known to 
influence packing and fluidity of the lipid bilayer (Ladbrooke et al., 1968). Interestingly, Patel et 
al. (Patel et al., 2001) report that the entrapment of BPO was improved by cholesterol presence 
until a threshold concentration was reached, where further increase in cholesterol content decreased 
the encapsulation efficiency of the liposomes. It would be therefore interesting to investigate if 
cholesterol could improve the encapsulation of BPO also in DAC processed liposomes in future 
studies.  
Taking into account that most of the active pharmaceutical ingredients applied in transdermal and 
dermal drug delivery exhibit a low water solubility (Haque et al., 2015), the relatively high 
encapsulation efficiency obtained with CAM and BPO is promising, and is suggesting that an 
increased number of active ingredients could be successfully entrapped into liposomes using DAC. 




(nm ± SD) 
PI 
(AU ± SD) 
Z-potential 
(mV ± SD) 
Entrapment 
efficiency 
(% ± SD) 
Empty liposomes 131.6 ± 9.1 0.14 ± 0.02 6.5 ± 2.7 - 
BPO-Lip 146.2 ± 7.6 0.11 ± 0.02 9.6 ± 1.7 51.0 ± 7.7 
CAM-Lip 143.4 ± 6.4 0.19 ± 0.08 8.0 ± 2.4 60.6 ± 3.3 
BPO-CAM-Lip 137.6 ± 5.5 0.08 ± 0.02 5.3 ± 3.0 
48.1 ± 8.1 (BPO) 




4.2.2. Loss of lipids 
As already mentioned, one of the main advantages of the DAC method is that all processing is 
performed in the same container, and that no transfer of material is required during the 
manufacturing. Consequently, the loss of material is expected to be avoided, contrary to other 
processing methods such as high-pressure homogenization, probe sonication and filter extrusion. 
To demonstrate this advantage, a phosphorus assay was performed to determine the lipid recovery 
from DAC. Since processing, subsequent dilution and mixing of the VPGs to liposomal dispersion 
take place in the same container, the only loss of lipids we were able to quantify was due to a 
volume loss during sample transfer and characterization. As seen in Figure 3, the lipid recovery 
was around 100% for all formulations except BPO-Lip, which had a recovery of 96%. The effect 
of volume loss on lipid recovery is further illustrated by evaluating the recovery after the separation 
of unentrapped drug from entrapped drug. BPO-Lip, which were filtered through a 0.22 µm filter 
to remove unentrapped drug, exhibited no loss of lipids, while CAM-Lip and BPO-CAM-Lip that 
were dialyzed or dialyzed and filtered, respectively, lost around 13% of original lipid content. 
 
Figure 3: Lipid recovery (n = 3, except for BPO-Lip where n = 2). 
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4.3. In vitro drug release  
Co-encapsulation of drugs into the same nanocarrier might change the drug release profile of the 
individual drugs if an interaction between the two drugs takes place in the liposome bilayer, or the 
packing or integrity of the liposome membrane is changed. To investigate if this was the case for 
our combination formulation, BPO-CAM-Lip, we performed an in vitro drug release study, using 
a standard Franz diffusion cell system, to compare the release profile from all the three liposome 
formulations (BPO-Lip, CAM-Lip and BPO-CAM-Lip, respectively). Since preliminary studies 
with the two drugs in solution alone and in combination showed that the release profile did not 
change for neither BPO nor CAM when combined, we decided to use a solution of BPO-CAM in 
PG as the common control during the release experiments of the liposomal formulations. 
The liposomal dispersions are expected to provide a sustained release of the drugs as compared to 
drugs in solution. Our results (Figure 4) showed that CAM demonstrated a sustained release, and 
the release was not influenced in any way by the presence of BPO in the combined formulations, 
as the CAM release from BPO-CAM-Lip was the same as the release from CAM-Lip. However, 
BPO was retained in the control solution (BPO-CAM-Sol), the BPO-Lip formulation and the BPO-
CAM-Lip formulation (Figure 4). The observed absence of release of BPO during the release 
experiment might be explained by limited water solubility of BPO. Although there are successful 
reports that demonstrate in vitro release from BPO- and BPO-tretinoin-containing niosomes (Goyal 
et al., 2015; Gupta et al., 2014), the presence and amount of organic solvent in the acceptor phase 
used in these studies would most likely interfere with the integrity of the liposomal carrier. 
Moreover, it would also limit our ability to observe the potential sustained release from the 
liposome formulation. To improve BPO solubility in the acceptor chamber, while avoiding 
disruption of the liposome membrane, we therefore performed some preliminary release studies 
using a dispersion of empty liposomes (size < 400 nm) and PEG 400:water (9:1 v/v) mixture as the 
acceptor phases, respectively. Despite these changes, we still failed to detect any release of BPO 
from any of the formulations, and thus decided to perform the release study with PBS as the 
acceptor phase. In order to fully reveal how the liposome formulation influence the partition of the 
drug into the skin, an artificial in vitro skin model or an in vivo model could have been used (Flaten 
et al., 2015). However, since liposomes for topical application to the skin also require a suitable 
vehicle for the final product development, such as hydrogel or a cream/lotion, our current main 
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objective was to observe possible interactions of the drugs in the liposomal carrier and determine 
whether the carrier influenced the drug release as compared to non-encapsulated drugs. Moreover, 
we indirectly proved that BPO is released from the nanocarrier in the cell viability assay (Table 2 
and Figure 5), as BPO in all formulations gave the most prominent effect of the cell viability.   
 
Figure 4: In vitro release of BPO and CAM from liposomes (n = 3). 
 
4.4. Influence of liposomal BPO and CAM on cell viability 
For skin infections such as acne, the topical route of administration is preferred due to the delivery 
of a higher concentration of drug into the desired infected area relative to what is achieved when 
the same drug is administered systemically. In addition, oral antibiotics are associated with possible 
severe adverse effects and high cost, as well as development of antimicrobial resistance. Local 
treatment of acne is less likely to cause systemic adverse effects and toxicity, but are usually 
associated with local irritation of the skin (Vyas et al., 2014). Liposomal drug delivery in topical 
treatment might be advantageous, as drug penetration and retention might be increased, a sustained 
release provided, lowering the required drug concentration needed to obtain effect from treatment 
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(Castro and Ferreira, 2008). In addition, poorly soluble drugs might be solubilized by the lipid 
bilayer of the liposomes (Yang et al., 2009), and liposomal targeting of pilosebaceus structures is 
achieved (Lieb et al., 1992). To evaluate the relative skin irritation as an effect of liposomal 
delivery, we applied the MTT assay on HaCaT cells. Cell viability was measured at drug 
concentrations corresponding to a liposome sample concentration between 0.1-4.0% (v/v), 
equivalent to 5-200 μg/ml CAM and 0.75-30 μg/ml BPO, respectively. To determine the potential 
cytotoxic effect of empty vesicles, we also investigated the effect of ethanol and empty liposomes 
in the same concentration range as applied in the drug formulations. The results showed that empty 
liposomes were more toxic (87.7 ± 1.3% cell viability) than ethanol (96.4 ± 1.8% cell viability). A 
decrease in proliferation of keratinocytes when incubated with liposomes in vitro has previously 
been reported by Bonnekoh et al. (Bonnekoh et al., 1991) and Pitto et al. (Pitto et al., 1999), and 
could be linked to increased cellular lipid fluidity of keratinocytes during the incubation (Bonnekoh 
et al., 1991). Pitto et al. also observed that the cells associated more efficiently with liposomes that 
contained soya lecithin, the lipid applied in this study (Pitto et al., 1999). An innate toxicity of the 
carrier itself or a closer association between the carrier and the cell might also explain the higher 
cytotoxicity exhibited by CAM in liposomal formulation (CAM-Lip) than in solution (CAM-Sol). 
Liposome formulations containing BPO generally showed a lower toxicity as compared to the BPO 
solution, indicating that liposomes are able to protect HaCaT cells from the toxic effects of BPO, 
most probably caused by a delayed release of the drug from the carrier, thereby reducing BPO’s 
interaction with the cells. The presence of CAM in liposomes did not seem to increase the 
cytotoxicity of BPO, since both BPO-Lip and BPO-Sol exhibited the same toxicity as CAM-BPO-




Table 2.   Cell toxicity post dilution 1:25 in growth medium (n = 3). 
Samples name Formulation (diluted 1:25 (corr. to 4% v/v)  Cell viability post 
treatment 
(% ± SD) 
RPMI Growth media (negative control) 99.7 ± 1.5 
Triton 2% Positive control 9.1 ± 0.6 
Ethanol   
Vehicles 
96.4 ± 1.8 
Empty 
liposomes 




28.3 ± 1.3 
CAM-Lip 78.4 ± 1.3 
BPO-Lip 28.9 ± 0.6 
CAM-BPO-Sol  
Drug dissolved in 96% ethanol 
 
12.7 ± 0.2 
CAM-Sol 95.5 ± 2.3 
BPO-Sol 12.8 ± 0.8 
 
Since only BPO-containing liposomes exhibited cytotoxicity at higher concentration, only the 
BPO-containing formulation were included in concentration-dependency experiments (Figure 5). 
Interestingly, the results indicate that the cytotoxicity of the liposomes attributed more to the total 
toxicity of the sample at lower sample concentrations, further supporting the reported findings of 
Bonnekoh et al. (Bonnekoh et al., 1991) and Pitto et al. (Pitto et al., 1999) regarding the influence 
of liposomes on cell proliferation. At lower concentrations (< 3-4%, v/v), dual-drug liposomes 




Figure 5. Effect of formulation concentration on the HaCaT cells viability (n = 3).  
 
The general BPO toxicity observed in this study is not surprising, since BPO is known to exhibit a 
keratolytic effect in addition to its antimicrobial properties (Waller et al., 2006). BPO-containing 
drug products are also known to cause considerable skin dryness and irritation, sometimes leading 
to the discontinuation of the treatment (Tripathi et al., 2013). Marketed products such as ointments 
or washes containing BPO are today available in a higher concentrations range, from 2.5 to 10% 
(w/v). However, Mills et al. (Mills et al., 1986) compared the efficacy of 2.5, 5 and 10% BPO in 
gels after an 8 week, twice-daily treatment regime, and concluded that all three formulations had 
similar efficacy in relation to reduction of number of papules and pustules. Moreover, the use of 
10% BPO gel formulation was associated with higher frequency and severity of adverse effects; 
peeling, erythema and burning, compared to the gel formulation containing only 2.5% BPO. 
Okamoto et al. (Okamoto et al., 2016) also reported the minimum inhibitory concentration (MIC) 
values for BPO in the range of 128 to 256 µg/ml while investigating in vitro activity of BPO against 
P. acnes, and Gupta et al. determined BPO’s MIC-value for S. epidermidis to be 28 µg/ml (Gupta 
21 
 
et al., 2014). Based on these evidences, our liposome formulation containing approximately 750 
µg/ml BPO should have a sufficiently high concentration to demonstrate a pronounced effect 
against both P. acne and S. epidermidis. It would therefore be interesting to see if it is possible to 
decrease BPO’s toxicity further by optimization of the liposomal carrier system and to include the 
BPO-containing liposomes in a suitable gel vehicle. Finally, the lack of cytotoxicity observed for 
CAM in our cell toxicity study makes it an even more promising antibiotic for further application 
in the topical liposomal formulations. 
 
5. Conclusion 
We have successfully demonstrated that DAC is a suitable method for co-encapsulation of BPO 
and CAM into a liposomal carrier. Co-encapsulation could be performed without any detectable 
interaction or influence of the two drugs on liposomal characteristics or release profiles. In addition, 
we were also able to develop a novel HPLC method for the simultaneous detection of BPO and 
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